Sexual dysfunction after Rezum therapy for benign prostatic hyperplasia: A scoping review for the current insights and findings

Abstract

Benign prostatic hyperplasia (BPH) is a common condition among aging men, often leading to lower urinary tract symptoms (LUTS) of varying severity. Both medical and surgical treatments for BPH can negatively impact sexual function, affecting patients' overall quality of life. This has highlighted the need for minimally invasive interventions that minimize sexual side effects. Rezum, a water vapor therapy, has gained popularity in managing BPH and LUTS due to its proposed potential to preserve sexual function. This scoping review examines the impact of Rezum therapy on sexual function in patients treated for BPH. The review was conducted following the Joanna Briggs Institute (JBI) methodology for scoping reviews. A comprehensive search was performed using the PubMed and Scopus databases up to August 2024. Articles were included if they involved patients treated with Rezum for BPH and reported the effect of Rezum on sexual function using validated scoring tools. A total of 15 studies encompassing 2,425 patients, met the inclusion criteria. Erectile function was assessed in all studies using the International Index of Erectile Function (IIEF) scores. Of these, seven studies reported no significant changes in erectile function scores, six demonstrated improvements, and two reported a significant decline. Ejaculatory function was evaluated using the Male Sexual Health Questionnaire (MSHQ). The MSHQ-Bother score was reported in seven studies, with three indicating improvement and none reporting deterioration. The MSHQ-Function score was reported in eight studies, with only one study reporting a decline, while the remaining studies found no significant changes. In conclusion, Rezum therapy for managing BPH shows favorable outcomes for sexual function or, at the very least, does not negatively impact it. These findings can guide patient counseling, especially for those seeking to preserve ejaculation. Further research is needed to compare Rezum with other treatment options regarding sexual function.

Keywords

benign prostate hyperplasia / orgasmic disorders / Rezum / sexual dysfunction

References

[1] Langan RC . Benign prostatic hyperplasia. Primary Care Clin Office Pract. 2019; 46: 223- 32.

[2] Lee C , Kozlowski JM , Grayhack JT . Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate. 1997; 31: 131- 8.

[3] Auffenberg GB , Helfand BT , McVary KT . Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am. 2009; 36: 443- 59.

[4] Lokeshwar SD , Harper BT , Webb E , Jordan A , Dykes TA , Neal Jr., DE , et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019; 8 (5): 529- 39.

[5] Patel N , Parsons J . Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014; 30: 170- 6.

[6] Berry SJ , Coffey DS , Walsh PC , Ewing LL . The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132: 474- 9.

[7] Roehrborn CG . Benign prostatic hyperplasia: an overview. Rev Urol. 2005; 7 Suppl 9: (Suppl 9): S3- S14.

[8] Awedew A.F. , Han H. , Abbasi B. , Abbasi-Kangevari M. , Ahmed M.B. , Almidani O. , et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longevity. 2022; 3 (11): e754- 76.

[9] McConnell JD , Roehrborn CG , Bautista OM , Andriole GL , Dixon CM , Kusek JW , et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349: 2387- 98.

[10] Andersson KE , de Groat WC , McVary KT , Lue TF , Maggi M , Roehrborn CG , et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011; 30: 292- 301.

[11] Lim KB . Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017; 4 (3): 148- 51.

[12] Kirby M , Chapple C , Jackson G , Eardley I , Edwards D , Hackett G , et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract. 2013; 67: 606- 18.

[13] Rosen RC , Link CL , O'Leary MP , Giuliano F , Aiyer LP , Mollon P . Lower urinary tract symptoms, and sexual health: the role of gender, lifestyle and medical comorbidities. BJU Int. 2009; 103 (Suppl 3): 42- 7.

[14] Schiff JD , Mulhall JP . The link between LUTS and ED: clinical and basic science evidence. J Androl. 2004; 25 (4): 470- 8.

[15] Blanker MH , Bohnen AM , Groeneveld FPMJ , Bernsen RMD , Prins A , Thomas S , et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc. 2001; 49 (4): 436- 42.

[16] McVary KT . Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol. 2005; 47 (6): 838- 45.

[17] Giuliano F . Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006; 97 (Suppl 2): 34- 8.

[18] Manfredi C , García-Gómez B , Arcaniolo D , García-Rojo E , Crocerossa F , Autorino R , et al. Impact of surgery for benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis of erectile function and ejaculatory function. European Urology Focus. 2022; 8 (6): 1711- 32.

[19] Magistro G , Chapple CR , Elhilali M , Gilling P , McVary KT , Roehrborn CG , et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017; 72: 986- 97.

[20] McVary KT , Miller LE , Bhattacharyya S , DeRouen K , Turner E , Zantek P , et al. Water vapor thermal therapy in men with prostate volume ≥80 cm³: a systematic review and meta-analysis. Urology. 2024; 184: 244- 50.

[21] Khalil IA , Aldeeb M , Mohammed A , Awad K , Ibrahim T , Al-Zoubi RM , et al. The role of Rezum in the management of refractory urinary retention due to benign prostate hyperplasia: a literature review. Arab J Urol. 2023; 21 (3): 185- 9.

[22] Abid A , Piperdi H , Babar M , Loloi J , Moutwakil A , Azhar U , et al. Minimally invasive surgical therapies for benign prostatic hyperplasia in the geriatric population: a systematic review. Prostate. 2024; 84 (10): 895- 908.

[23] McVary KT , Gittelman MC , Goldberg KA , Patel K , Shore ND , Levin RM , et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021; 206 (3): 715- 24.

[24] Busetto GM , Lombardo R , De Nunzio C , Santoro G , Tocci E , Schiavone N , et al. Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH. Prostate Cancer Prostatic Dis. Published online April 13, 2014.

[25] Leong JY , Patel AS , Ramasamy R . Minimizing sexual dysfunction in BPH surgery. Current Sexual Health Rep. 2019; 11 (3): 190- 200.

[26] Peters MDJ , Godfrey C , McInerney P , et al. Chapter 11: scoping reviews (2020 version). In: Aromataris E, Munn Z, editors. JBI manual for evidence synthesis. JBI, Australia; 2020; 407- 13.

[27] Dixon CM , Cedano ER , Pacik D , Vit V , Varga G , Wagrell L , et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016; 8: 207- 16.

[28] Roehrborn CG , Gange SN , Gittelman MC , Goldberg KA , Patel K , Shore ND , et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017; 197 (6): 1507- 16.

[29] Alegorides C , Fourmarier M , Eghazarian C , Lebdai S , Chevrot A , Droupy S . Treatment of benign prostate hyperplasia using the Rezum^® water vapor therapy system: results at one year. Progrès en Urologie. 2020; 30 (12): 624- 31.

[30] Siena G , Cindolo L , Ferrari G , Maruzzi D , Fasolis G , Condorelli SV , et al. Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World J Urol. 2021; 39 (10): 3875- 80.

[31] McVary KT , El-Arabi A , Roehrborn C . Preservation of sexual function 5 years after water vapor thermal therapy for benign prostatic hyperplasia. Sex Med. 2021; 9 (6): 100454.

[32] Fernández-Guzmán E , Asensio Matas A , Capape Poves V , Rioja Zuazu J , Garrido Abad P , Martínez-Salamanca JI , et al. Resultados preliminares de un trabajo multicéntrico a nivel nacional para el tratamiento de STUI secundario a hiperplasia benigna de próstata mediante el sistema con vapor de agua Rezūm^®. Actas Urológicas Españolas. 2022; 46 (5): 310- 6.

[33] Whiting D , Noureldin M , Abdelmotagly Y , Johnston MJ , Brittain J , Rajkumar G , et al. Real-world early outcomes and retreatment rates following water vapour ablative therapy for symptomatic benign prostatic hyperplasia. European Urology Open Science. 2022; 39: 72- 8.

[34] Elterman D , Bhojani N , Vannabouathong C , Chughtai B , Zorn KC . Large, multi-center, prospective registry of rezūm water vapor therapy for benign prostatic hyperplasia. Urology. 2022; 165: 261- 7.

[35] Elterman D , Bhojani N , Vannabouathong C , Chughtai B , Zorn KC . Rezūm therapy for ≥80-mL benign prostatic enlargement: a large, multicentre cohort study. BJU Int. 2022; 130 (4): 522- 7.

[36] Campobasso D , Siena G , Chiodini P , Conti E , Franzoso F , Maruzzi D , et al. Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study. Prostate Cancer Prostatic Dis. 2023; 26 (2): 410- 4.

[37] Ghahhari J , Sountoulides P , Campobasso D , Faieta A , Sessa F , Viola L , et al. Mid-term results of water vapor thermal therapy in patients with lower urinary tract symptoms related to benign prostatic hyperplasia. Front Urol. 2022; 2: 990560.

[38] Schwartzmann I , García Barreras S , D'Anna M , Parejo V , Torneo Ruiz I , Tagalos Muñoz AC , et al. Terapia termal con vapor de agua: variaciones técnicas entre hospitales universitarios españoles y eficacia a 2 años de seguimiento. Actas Urológicas Españolas. 2023; 47 (10): 668- 74.

[39] Cindolo L , Morselli S , Campobasso D , Conti E , Sebastiani G , Franzoso F , et al. One-year outcomes after water vapor thermal therapy for symptomatic benign prostatic hyperplasia in an unselected Italian multicenter cohort. Minerva Urol Nephrol. 2023; 75 (2): 203- 9.

[40] Nguyen V , Winograd J , Codelia-Anjum AJ , Zorn KC , Elterman D , Bhojani N , et al. Feasibility assessment of catheter-free water vapor thermal therapy for treatment of benign prostatic hyperplasia. World J Urol. 2024; 42 (1): 383.

[41] Hawks-Ladds N , Cook R , Babar M , Zhu M , Schulz A , Loloi J , et al. Four years of real-world sexual function outcomes after Rezum therapy in men with and without baseline erectile dysfunction. J Sex Med. 2024: qdae087.

[42] Taher A . Erectile dysfunction after transurethral resection of the prostate: incidence and risk factors. World J Urol. 2004; 22: 457- 60.

[43] Parsons JK , Dahm P , Köhler TS , Lerner LB , Wilt TJ . Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2020. J Urol. 2020; 204: 799- 804.

[44] Checcucci E , Veccia A , De Cillis S , Piramide F , Volpi G , Amparore D , et al. New ultra-minimally invasive surgical treatment for benign prostatic hyperplasia: a systematic review and analysis of comparative outcomes. Eur Urol Open Sci. 2021; 33: 28- 41.

[45] Lebdai S , Chevrot A , Doizi S , Pradere B , Delongchamps NB , Benchikh A , et al. Do patients have to choose between ejaculation and miction? A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment. World J Urol. 2019; 37 (2): 299- 308.

[46] Yang J , Wu W , Amier Y , Li X , Wan W , Liu C , et al. Efficacy and safety of Water Vapor Thermal Therapy in the treatment of benign prostate hyperplasia: a systematic review and single-arm Meta-analysis. BMC Urol. 2023; 23 (1): 72.

[47] Gosso AA , Amparore D , Di Maida F , de Cillis S , Cocci A , Di Dio M , et al. Comparison of perioperative and short-terms outcomes of en-bloc Holmium laser enucleation of the prostate (HoLEP) and robot-assisted simple prostatectomy: a propensity-score matching analysis. Prostate Cancer Prostatic Dis. 2023; 27: 478- 84.

[48] Porreca A , Schiavina R , Romagnoli D , Corsi P , Salvaggio A , D'Agostino D , et al. T-L technique for HoLEP: perioperative outcomes of a large single-centre series. Cent Eur J Urol. 2021; 74: 366- 71.

[49] Gil-Vernet JM , Alvarez-Vijande R , Gil-Vernet A , Gil-Vernet JM . Ejaculation in men: a dynamic endorectal ultrasonographical study. Br J Urol. 1994; 73 (4): 442- 8.

[50] Barazani Y , Stahl PJ , Nagler HM , Stember DS . Management of ejaculatory disorders in infertile men. Asian J Androl. 2012; 14 (4): 525- 9.

[51] Liao J , Zhang X , Chen M , Li D , Tan X , Gu J , et al. Transurethral resection of the prostate with preservation of the bladder neck decreases postoperative retrograde ejaculation. Wideochir Inne Tech Maloinwazyjne. 2019; 14 (1): 96- 101.

[52] Muntener M , Aellig S , Kuettel R , Gehrlach C , Sulser T , Strebel RT . Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol. 2007; 52 (2): 510- 6.

[53] Doppalapudi S.K. , Gupta N . What is new with rezūm water vapor thermal therapy for LUTS/BPH? Curr Urol Rep. 2021; 22 (1): 4.

[54] Wylie K , Kenney G . Sexual dysfunction and the ageing male. Maturitas. 2010; 65 (1): 23- 7.

[55] Soans J , Vazirian-Zadeh M , Kum F , Dhariwal R , Breish MO , Singh S , et al. Can surgical treatment for benign prostatic hyperplasia improve sexual function? A systematic review. Aging Male. 2020; 23 (5): 770- 9.

RIGHTS & PERMISSIONS

The Author(s). UroPrecision published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.